Sensidose has developed a system for individual, finely titrated treatment of Parkinson's disease. The company's microtablets Flexilife contains a small dose of levodopa, which allows the total dose to be tailored to each patient's needs by adjusting the number of tablets given. Flexilev is dosed using the MyFID dose dispenser, which is currently undergoing reprogramming to address the shortage of semiconductor components.
The company's treatment is offered to patients in Scandinavia, where it is now focusing on increasing sales, while geographical expansion to more markets is underway. Sensidose initially plans to launch the treatment in Poland and Finland.
Strengthens the organization ahead of the expansion phase
To accelerate ahead of ongoing and further expansion, the company has chosen to strengthen the organization with Philip Slätis in the role of Chief Operating Officer and Vice President. Philip Slätis most recently came from a position as a business developer at the pharmaceutical company Unimedic where he was responsible for expansion of the company's products and services and in-licensing of new products.
Before that, he held positions at several large life science companies such as Sanofi, AstraZeneca, Baxter, Novo Nordisk and AmgenIn a press release, Philip says that he looks forward to taking up his position as COO/Vice President of Sensidose on November 1, 2022:
»I am very happy and grateful to have the opportunity to join Sensidose at an incredibly exciting time. The need for more individualized treatment, together with Sensidose technology and ambitious growth plans, is a unique opportunity«
CEO welcomes Philip Slätis to Sensidose
According to the company, Philip Släti's broad experience from the pharmaceutical market and international networks will be an important asset in Sensidose's expansion in existing and new markets. To learn more about the recruitment, BioStock contacted the company's CEO Jack Spira:
Jack, why do you see a need for another person in management right now and what expectations do you have for what Philip Slätis can contribute?
– Although Sensidose is both a medical device and pharmaceutical company, it is the pharmaceuticals that we sell and derive our revenue from. Philips' broad experience and knowledge from this industry and his international network of contacts will strengthen our opportunities to expand in accordance with our plans.
»Philips' broad experience and knowledge from this industry and his international network of contacts will strengthen our opportunities to expand in accordance with our plans.«
What will be Philip Släti's most important tasks in the role of COO/Deputy CEO?
– We are a small organization and have not had sufficient resources to run all projects and our geographical expansion. With Philip, we will receive significant reinforcement in business development and also in marketing and several other areas that he has worked in. In addition to the immediate opportunities with Flexilev and MyFID, we see that for our new upcoming manual dosing machine, Orafid, there are great opportunities both within Parkinson's and for other diagnoses. So Philip Slätis will have an important task in realizing our plans to get this product out internationally.
